Abstract
Financial toxicity is recognised as an important adverse consequence of cancer treatment that may be associated with impaired health-related quality of life (HRQOL). We aim to perform a systematic review and meta-analysis on studies investigating the relationship between HRQOL and subjective financial toxicity measured with the Comprehensive Score for Financial Toxicity (COST) instrument in cancer patients and survivors.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
